Targeting Cancer Cells’ Compensatory Pathways: Cell-Cycle Targets and Synthetic Lethality
Background: The paradox of compensatory pathways that sustain cell division
Pathways that cancer cells rely on to compensate for disrupted cell-cycle control can become targets for cancer therapy. This review in Cancer Science surveys drugs and synthetic-lethality research aimed at these dependencies. It frames cell-cycle abnormalities as changes that both support cancer-cell proliferation and create vulnerabilities that may be exploited therapeutically.
Cell division requires accurate DNA replication and chromosome segregation. Cyclin-dependent kinases (Cdks) drive progression through the stages of division, while checkpoints detect DNA damage or abnormal chromosome attachment and halt progression. In cancer, persistent growth signals and loss of checkpoint function disrupt this balance. Cancer cells can nevertheless survive in part by relying on remaining compensatory pathways. The treatment strategies highlighted in the review seek to disrupt this dependence.
Key findings: Halting division or allowing it to proceed despite damage
The review distinguishes cell-cycle-targeting strategies by how they work. Cdk4/6 inhibition prevents entry into the DNA synthesis phase. Palbociclib, ribociclib, and abemaciclib have been used clinically for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The authors also describe prior research suggesting that when growth signals persist after proliferation stops, cells can grow excessively, accumulate damage, and enter senescence. In addition to temporarily halting division, this approach may induce a state in which cells cannot re-enter the cell cycle.
By contrast, strategies that disable the remaining brakes are being explored in cancer cells with high DNA replication stress. Replication stress is a condition in which DNA replication does not proceed smoothly. Checkpoint signals such as ATR, Chk1, and Wee1 help provide cells with time to repair damage. Inhibiting these pathways can drive cells into mitosis before replication is complete or while damage remains, potentially causing lethal division failure. The review describes clinical trials combining checkpoint inhibitors with drugs that increase replication stress, such as gemcitabine.
Synthetic lethality is a relationship in which defects in two gene functions together make cell survival difficult. It can be exploited by inhibiting a target that pairs with an abnormality already present in cancer cells. Among the examples covered in the review, amplification or overexpression of CCNE1, the gene encoding cyclin E, increases replication stress; these cancer cells may depend on Myt1, which prevents premature activation of Cdk1. Inhibiting Myt1 promotes division before DNA replication is complete, exploiting this vulnerability. The authors also describe a study that used CRISPR genetic screening to identify IGF2BP2 dependence in cancers with polo-like kinase 1 (PLK1) overexpression. These findings come from individual studies cited by the review.
Implications and outlook: The gap between target discovery and patient treatment
Cell-cycle targets are at different stages of development. In addition to Cdk4/6 inhibitors used in clinical practice, the review describes samuraciclib, a Cdk7 inhibitor evaluated in a phase 1 study in patients with breast cancer. Early clinical trials or preclinical target discovery alone do not establish efficacy in patients.
Selectivity and resistance also remain challenges. The review links loss of retinoblastoma protein (RB), cyclin E amplification, and compensatory Cdk2 activation to resistance to Cdk4/6 inhibitors. Aurora kinases and PLK1 are essential in normal cells as well, and inhibitor toxicity has limited their clinical use. This is why effects on normal tissues must be assessed even after a compensatory pathway has been identified in a particular tumor. Follow-up research that examines dependencies under specific tumor conditions alongside drug responses will help determine the value of these treatment strategies.
For detailed mechanisms and cited studies, see the full Cancer Science review and the paper’s bibliographic record and abstract.
Cancer & Metabolism Reviews, Published June 2026.
Summary: Bypassing the severe systemic toxicities and low therapeutic indices that historically challenge non-selective chemotherapy regimens, this comprehensive investigation details cell cycle vulnerability mapping in oncology. Harnessing high-throughput CRISPR-Cas9 genetic screens linked with quantitative multi-kinase assays, the computing platform models the sequential kinetics of cyclin-dependent kinases (Cdks), checkpoint kinases, and mitotic segregation machinery. The framework demonstrates that the loss of structural checkpoint checkpoints in tumor lines uncouples mitogenic amplification from homeostatic survival, rendering cancer cells selectively sensitive to targeted targeted perturbations. This molecular profiling refines unique synthetic lethal dependencies, delivering a standardized computational baseline to optimize universal patient stratification and guide prospective structure-based rational drug design.
The review points to a research strategy that looks not only at the genes driving proliferation, but also at compensatory pathways that help cells tolerate those abnormalities. For example, a development team studying CCNE1-amplified tumors could use Myt1 dependence to support candidate-target selection, then compare drug responses and effects on normal cells using tumor models with that feature. CRISPR screening offers a way to uncover such hidden dependencies. However, a link between a genetic abnormality and target dependence does not by itself establish a validated patient-selection test or prescribing criterion. Drug development still needs to assess response-predictive markers, resistance pathways, and toxicity to normal tissues. This review can help prioritize those follow-up studies.